source
- FDA approves Revolution Medicines’ pancreatic cancer drug Rasonque, but patients face delayed accessThe U.S. Food and Drug Administration has granted approval to Rasonque, a new therapy for pancreatic cancer developed by Revolution Medicines. The decision follows clinical data that showed the dru…
- Roivant's experimental pulmonary hypertension drug meets Phase 2 goalsRoivant announced that its experimental drug mosliciguat achieved the primary endpoint in a 16‑week Phase 2 trial for pulmonary hypertension, a serious lung condition. The study showed a 56% reduc…